185 related articles for article (PubMed ID: 21942462)
1. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
Wertz DA; Chang CL; Stephenson JJ; Zhang J; Kuhn RJ
J Med Econ; 2011; 14(6):759-68. PubMed ID: 21942462
[TBL] [Abstract][Full Text] [Related]
2. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
3. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Gibson RL; Emerson J; Mayer-Hamblett N; Burns JL; McNamara S; Accurso FJ; Konstan MW; Chatfield BA; Retsch-Bogart G; Waltz DA; Acton J; Zeitlin P; Hiatt P; Moss R; Williams J; Ramsey BW
Pediatr Pulmonol; 2007 Jul; 42(7):610-23. PubMed ID: 17534969
[TBL] [Abstract][Full Text] [Related]
4. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
5. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.
Murphy TD; Anbar RD; Lester LA; Nasr SZ; Nickerson B; VanDevanter DR; Colin AA
Pediatr Pulmonol; 2004 Oct; 38(4):314-20. PubMed ID: 15334509
[TBL] [Abstract][Full Text] [Related]
6. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
7. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
9. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
10. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
[TBL] [Abstract][Full Text] [Related]
11. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
13. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.
Nasr SZ; Sakmar E; Christodoulou E; Eckhardt BP; Streetman DS; Strouse PJ
Pediatr Pulmonol; 2010 May; 45(5):440-9. PubMed ID: 20425851
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis.
Iles R; Legh-Smith J; Drummond M; Prevost A; Vowler S
J Cyst Fibros; 2003 Sep; 2(3):120-8. PubMed ID: 15463860
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
Stelmach I; Korzeniewska A; Stelmach W
Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
17. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Sansgiry SS; Joish VN; Boklage S; Goyal RK; Chopra P; Sethi S
J Med Econ; 2012; 15(2):219-24. PubMed ID: 22084956
[TBL] [Abstract][Full Text] [Related]
19. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.
Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I
Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
